ENGOT-EN5/GOG- 3055/SIENDO

Trial Description: 
A randomized, double-blind, phase 3 trial of maintenance with selixexor/placebo after combination chemotherapy for patients with advanced or recurrent endometrial cancer.
Lead Cooperative Group: 
Participating Groups: 
Disease Site: 
Endometrial
Trial Status: 
Closed to Recruitment
Contact person: 
ivergote